Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 190

1.

Future directions in the treatment of cholangiocarcinoma.

Zhu AX.

Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):355-361. doi: 10.1016/j.bpg.2015.02.010. Epub 2015 Feb 19. Review.

PMID:
25966434
2.

Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism.

Sahani DV, Hayano K, Galluzzo A, Zhu AX.

AJR Am J Roentgenol. 2015 Apr;204(4):776-81. doi: 10.2214/AJR.14.13223.

PMID:
25794066
3.

Erratum to: The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology.

Ferrone CR, Ting DT, Shahid M, Konstantinidis IT, Sabbatino F, Goyal L, Rice-Stitt T, Mubeen A, Arora K, Bardeesy N, Miura J, Gamblin TC, Zhu AX, Borger D, Lillemoe KD, Rivera MN, Deshpande V.

Ann Surg Oncol. 2015 Mar 19. [Epub ahead of print] No abstract available.

PMID:
25786746
4.

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.

Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M, Deshpande V, Zhu AX, Lai A, Min B, Hoshida Y, Avruch J, Sia D, Campreciós G, McClatchey AI, Llovet JM, Morrissey D, Raj L, Bardeesy N.

Cell Rep. 2015 Mar 10. pii: S2211-1247(15)00173-4. doi: 10.1016/j.celrep.2015.02.027. [Epub ahead of print]

5.

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.

Huynh H, Hao HX, Chan SL, Chen D, Ong R, Soo KC, Pochanard P, Yang D, Ruddy D, Liu M, Derti A, Balak MN, Palmer MR, Wang Y, Lee BH, Sellami D, Zhu AX, Schlegel R, Huang A.

Mol Cancer Ther. 2015 May;14(5):1224-35. doi: 10.1158/1535-7163.MCT-14-0768. Epub 2015 Feb 27.

PMID:
25724664
6.

Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.

Deipolyi AR, Oklu R, Al-Ansari S, Zhu AX, Goyal L, Ganguli S.

J Vasc Interv Radiol. 2015 Apr;26(4):516-22. doi: 10.1016/j.jvir.2014.12.020. Epub 2015 Feb 18.

PMID:
25704226
7.

Self-catalysed aerobic oxidization of organic linker in porous crystal for on-demand regulation of sorption behaviours.

Liao PQ, Zhu AX, Zhang WX, Zhang JP, Chen XM.

Nat Commun. 2015 Feb 23;6:6350. doi: 10.1038/ncomms7350.

PMID:
25702689
8.

Microsatellite instability in gallbladder carcinoma.

Moy AP, Shahid M, Ferrone CR, Borger DR, Zhu AX, Ting D, Deshpande V.

Virchows Arch. 2015 Apr;466(4):393-402. doi: 10.1007/s00428-015-1720-0. Epub 2015 Feb 14.

PMID:
25680569
9.

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C.

Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.

PMID:
25599322
10.

Erratum to: The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology.

Ferrone CR, Ting DT, Shahid M, Konstantinidis IT, Sabbatino F, Goyal L, Rice-Stitt T, Mubeen A, Arora K, Bardeesey N, Miura J, Gamblin TC, Zhu AX, Borger D, Lillemoe KD, Rivera MN, Deshpande V.

Ann Surg Oncol. 2015 Jan 10. [Epub ahead of print] No abstract available.

PMID:
25575648
11.

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK.

J Clin Oncol. 2015 Feb 20;33(6):559-66. doi: 10.1200/JCO.2013.53.7746. Epub 2014 Dec 29.

PMID:
25547503
12.

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.

Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG.

Hepatology. 2015 May;61(5):1591-602. doi: 10.1002/hep.27665. Epub 2015 Mar 20.

PMID:
25529917
13.

The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology.

Ferrone CR, Ting DT, Shahid M, Konstantinidis IT, Sabbatino F, Goyal L, Rice-Stitt T, Mubeen A, Arora K, Bardeesey N, Miura J, Gamblin TC, Zhu AX, Borger D, Lillemoe KD, Rivera MN, Deshpande V.

Ann Surg Oncol. 2014 Dec 18. [Epub ahead of print]

PMID:
25519926
14.

Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma?

Hesketh RL, Zhu AX, Oklu R.

Diagn Interv Radiol. 2015 Jan-Feb;21(1):78-84. doi: 10.5152/dir.2014.14237.

15.

Intratumoral Vascular Shunting: Biomarker of Clinical Outcome and Source of Circulating Tumor Cells?

Deipolyi AR, Zhu AX, Oklu R.

Am J Clin Oncol. 2014 Oct 20. [Epub ahead of print]

PMID:
25333732
16.

Prospective trial with optical molecular imaging for percutaneous interventions in focal hepatic lesions.

Sheth RA, Arellano RS, Uppot RN, Samir AE, Goyal L, Zhu AX, Gervais DA, Mahmood U.

Radiology. 2015 Mar;274(3):917-26. doi: 10.1148/radiol.14141308. Epub 2014 Oct 10.

PMID:
25302707
17.

A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.

Goyal L, Wadlow RC, Blaszkowsky LS, Wolpin BM, Abrams TA, McCleary NJ, Sheehan S, Sundaram E, Karol MD, Chen J, Zhu AX.

Invest New Drugs. 2015 Feb;33(1):128-37. doi: 10.1007/s10637-014-0164-8. Epub 2014 Sep 24.

PMID:
25248753
18.

Hepatocellular Carcinoma: Can Circulating Tumor Cells and Radiogenomics Deliver Personalized Care?

Hesketh RL, Zhu AX, Oklu R.

Am J Clin Oncol. 2014 Sep 18. [Epub ahead of print]

PMID:
25238287
19.

A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors.

Hong TS, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, Niemierko A, Wolfgang JA, Lu HM, Adams J, Weyman EA, Arellano RS, Blaszkowsky LS, Allen JN, Tanabe KK, Ryan DP, Zhu AX.

Pract Radiat Oncol. 2014 Sep-Oct;4(5):316-22. doi: 10.1016/j.prro.2013.10.002. Epub 2013 Nov 22.

PMID:
25194100
20.

Hepatobiliary cancers, version 2.2014.

Benson AB 3rd, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H.

J Natl Compr Canc Netw. 2014 Aug;12(8):1152-82.

PMID:
25099447
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk